Abstract
Responsive drug delivery systems possess great potential in disease diagnosis and treatment. Herein, we develop an activatable prodrug and fluorescence imaging material by engineering the endogenous NAD(P)H:quinone oxidoreductase-1 (NQO1) responsive linker. The as-prepared nanomaterials possess the NQO1-switched drug release and fluorescence enablement, which realizes the tumor-specific chemotherapy and imaging in living mice. The enzyme-sensitive prodrug nanoparticles exhibit selectively potent anticancer performance to NQO1-positive cancer and ignorable off-target toxicity. This work provides an alternative strategy for constructing smart prodrug nanoplatforms with precision, selectivity, and practicability for advanced cancer imaging and therapy.
Keywords:
NQO1; enzyme; near-infrared imaging.; precise therapy; prodrug.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Biocompatible Materials / chemical synthesis
-
Biocompatible Materials / chemistry
-
Biocompatible Materials / pharmacology*
-
Cell Line
-
Cell Survival / drug effects
-
Drug Delivery Systems
-
Drug Liberation
-
Drug Screening Assays, Antitumor
-
Humans
-
Materials Testing
-
Mice
-
Molecular Structure
-
NAD(P)H Dehydrogenase (Quinone) / metabolism*
-
Nanoparticles / chemistry*
-
Neoplasms / diagnostic imaging
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Neoplasms, Experimental / diagnostic imaging
-
Neoplasms, Experimental / drug therapy
-
Neoplasms, Experimental / metabolism
-
Optical Imaging
-
Particle Size
-
Precision Medicine*
-
Prodrugs / chemical synthesis
-
Prodrugs / chemistry
-
Prodrugs / pharmacology*
Substances
-
Antineoplastic Agents
-
Biocompatible Materials
-
Prodrugs
-
NAD(P)H Dehydrogenase (Quinone)
-
NQO1 protein, human